Connecting Patients to ACTEMRA
ACTEMRA Access Solutions provides helpful access and reimbursement support to assist your patients and practice after ACTEMRA is prescribed.
We can help your patients and practice by providing:
We can help your patients and practice by providing:
Benefits investigations (BIs) to verify coverage and benefits reverification support
Prior authorization (PA) resources
Information about authorized specialty pharmacies (SPs) and specialty distributors
Sample billing and coding information
Resources for denials and appeals
The completion and submission of coverage- or reimbursement-related documentation are the responsibility of the patient and health care provider. Genentech makes no representation or guarantee concerning coverage or reimbursement for any service or item.
ACTEMRA [package insert]. South San Francisco, CA: Genentech, Inc.
ACTEMRA [package insert]. South San Francisco, CA: Genentech, Inc.
National Institutes of Health. COVID-19 Treatment Guidelines. https://www.covid19treatmentguidelines.nih.gov/tables/management-of-hospitalized-adults-summary/Accessed October 28, 2022.
National Institutes of Health. COVID-19 Treatment Guidelines. https://www.covid19treatmentguidelines.nih.gov/tables/management-of-hospitalized-adults-summary/Accessed October 28, 2022.
RECOVERY Collaborative Group. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2021;397:1637-1645.
RECOVERY Collaborative Group. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2021;397:1637-1645.
Salama C, Han J, Yau L, et al. Tocilizumab in patients hospitalized with Covid-19 pneumonia. N Engl J Med. 2021;384:20-30.
Salama C, Han J, Yau L, et al. Tocilizumab in patients hospitalized with Covid-19 pneumonia. N Engl J Med. 2021;384:20-30.
Rosas IO, Bräu N, Waters M, et al. Tocilizumab in hospitalized patients with severe Covid-19 pneumonia. N Engl J Med. 2021;384:1503-1516.
Rosas IO, Bräu N, Waters M, et al. Tocilizumab in hospitalized patients with severe Covid-19 pneumonia. N Engl J Med. 2021;384:1503-1516.
Rosas IO, Diaz G, Gottlieb RL, et al. Tocilizumab and remdesivir in hospitalized patients with severe COVID‑19 pneumonia: a randomized clinical trial. Intensive Care Med. 2021;47:1258-1270.
Rosas IO, Diaz G, Gottlieb RL, et al. Tocilizumab and remdesivir in hospitalized patients with severe COVID‑19 pneumonia: a randomized clinical trial. Intensive Care Med. 2021;47:1258-1270.
Data on file. EMPACTA CSR. Genentech, Inc.
Data on file. EMPACTA CSR. Genentech, Inc.
Smolen JS, et al. Arthritis Rheum. 2006;54:702-710.
Smolen JS, et al. Arthritis Rheum. 2006;54:702-710.
Scheller J, et al. Med Microbiol Immunol. 2006;195:173-183.
Scheller J, et al. Med Microbiol Immunol. 2006;195:173-183.
McGrath H, et al. Rheumatology. 2004;43:1323-1325.
McGrath H, et al. Rheumatology. 2004;43:1323-1325.
Browning JL, et al. Nat Rev Discov. 2006;5:564-576.
Browning JL, et al. Nat Rev Discov. 2006;5:564-576.
Choy E, et al. Rheum Dis Clin N Am. 2004;30:405-415.
Choy E, et al. Rheum Dis Clin N Am. 2004;30:405-415.
US Food and Drug Administration. Fact sheet for healthcare providers: emergency use authorization for ACTEMRA® (tocilizumab). Accessed August 12, 2022. https://www.fda.gov/media/150321/download.
US Food and Drug Administration. Fact sheet for healthcare providers: emergency use authorization for ACTEMRA® (tocilizumab). Accessed August 12, 2022. https://www.fda.gov/media/150321/download.
The information contained in this section of the site is intended for U.S. healthcare professionals only. Click "OK" if you are a healthcare professional.
The link you have selected will take you away from this site to one that is not owned or controlled by Genentech, Inc. Genentech, Inc. makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.